C07C 2603/99
Containing eight-membered rings
Official title: containing eight-membered rings
C07C2603/99 (Containing eight-membered rings) appears on 13 US grants and 27 published applications in this corpus.
Search patents in C07C- Granted patents
- 13
- Published applications
- 27
- Assignees
- 9
- Inventors
- 33
- Latest grant
- 17 May 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 1 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 1 |
| 2009 | 0 | 2 |
| 2010 | 1 | 3 |
| 2011 | 1 | 0 |
| 2012 | 1 | 1 |
| 2013 | 1 | 2 |
| 2014 | 0 | 1 |
| 2015 | 1 | 0 |
| 2016 | 1 | 0 |
| 2017 | 0 | 6 |
| 2018 | 0 | 1 |
| 2019 | 4 | 1 |
| 2020 | 0 | 3 |
| 2021 | 1 | 2 |
| 2022 | 1 | 1 |
| 2023 | 0 | 1 |
By publication year.
Recent patents
- Pleuromulin lauric acid ester with antibacterial activity and a method of preparing the same17 May 2022US 11,332,430 B1Xi'an Taikomed Pharmaceutical Technology Co., Ltd.
- Purification of pleuromutilin9 Feb 2021US 10,913,703 B2Nabriva Therapeutics AG
- Compound and organic electronic device comprising the same1 Oct 2019US 10,431,751 B2Shanghai Nichem Fine Chemical Co., Ltd.
- Compound and organic electronic device comprising the same24 Sep 2019US 10,424,744 B2Shanghai Nichem Fine Chemical Co., Ltd.
- Compound and organic electronic device comprising the same18 Jun 2019US 10,326,087 B2Nichem Fine Technology Co., Ltd.
- Compounds and methods to target glucose-stimulated phosphohistidine signaling and esophageal cancer growth28 Dec 2023US 2023/0416209 A1
- Pleuromutilin derivatives for the treatment of diseases mediated by microbes14 Jul 2022US 2022/0218713 A1Nabriva Therapeutics AG
- Pleuromutilin derivatives for the treatment of diseases mediated by microbes22 Apr 2021US 2021/0113571 A1Nabriva Therapeutics AG
- Novel fully synthetic and semisynthetic pleuromutilin derivatives as new antibiotics and their preparation22 Apr 2021US 2021/0115003 A1Yale University
- Pleuromutilin derivatives for the treatment of diseases mediated by microbes10 Sep 2020US 2020/0281933 A1Nabriva Therapeutics AG
Most cited
By later US patents
- Pleuromutilin derivatives having antibacterial activity2US 6,753,445 B2Biochemie Gesellschaft m.b.H. · 2004
- Pleuromutilin derivatives for the treatment of diseases mediated by microbes2US 8,071,643 B2Nabriva Therapeutics AG · 2011
- Pleuromutilin derivatives for the treatment of diseases mediated by microbes2US 8,153,689 B2Nabriva Therapeutics AG · 2012
- Purification of pleuromutilin1US 10,913,703 B2Nabriva Therapeutics AG · 2021
- Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group1US 7,790,767 B2Nabriva Therapeutics Forschungs GmbH · 2010